ClinicalTrials.gg
CompletedNCT04644978EustigmaUpdated Oct 27, 2022

European Study on the Attitude of Psychiatrists Towards Their Patients

An observational study in Mental Illness and Stigmatization, sponsored by Semmelweis University. Completed at 31 sites in 31 countries. Open to participants aged 24 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-27.

Sponsored by Semmelweis University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
4,245
Ages
24 Years and older
Sex
All
01

Study summary

Background: Many people think that people with mental disorders might be dangerous or unpredictable. These patients face various sources of disadvantages and experience discrimination on job interviews, in education, and housing. Mental health-related stigma (MHS) occurs not only within the public community, it is a growing issue among professionals as well.

Aim: The investigators designed a prospective, observational, multi-centre, international study of 35 European countries to investigate the MHS among medical specialists and trainees in the field of general adult and child and adolescent psychiatry.

Methods: An internet-based, anonymous survey will measure the stigmatizing attitude by using the local version of the Opening Minds Stigma Scale for Health Care Providers.

Presentation of the Results: The results of the research will be published in an international peer-reviewed journal. Furthermore, the research team will present the results at national and international conferences.

Read the detailed description

There is a rising interest in the examination of the MHS that has been mostly studied among community people. Numerous international studies have shown that people with mental illness are considered to be unpredictable and dangerous. These people often experience disadvantages in various situations, like job interviews, education, and housing.

The MHS has been much less examined among medical professionals and psychiatrists; however, studies have shown that it is prevalent among them as well.

A recent multi-centre study collected the positive and negative experiences of 777 people with schizophrenia regarding access to healthcare services in 27 countries. More than 17% of the patients experienced some kind of discrimination due to their mental illness when they sought medical care for physical problems. More than 38% felt that the medical staff was disrespectful during psychiatric services. Higher discrimination was found within the former Eastern Bloc countries.

Generally, psychiatrists tend to be more empathetic towards people with mental illnesses; however, the MHS could be observed among them as well. A few studies have also shown that their attitude is more negative than that of community people.

Based on the ambiguous results and the lack of studies focusing on the stigmatizing attitude of psychiatrists, the research team aimed to examine this important issue among medical professionals in the mental health field.

Aim of the study:

Our aim is to investigate the stigmatizing attitudes and behaviours of adult psychiatric and child and adolescent psychiatric professionals and trainees towards people with mental illness in European countries.

The results of our study will contribute to the expansion of the existing knowledge both on national and international levels. The outcome could be used for the development of anti-stigma programs and the improvement of therapeutic options in the future.

Structure of the research:

Our study is cross-sectional and multi-centred across 35 European countries. The research team would like to measure the extent of the stigmatizing attitude and its relationship with psychosocial factors.

  • Sociodemographic measures:

    • sociodemographic data: age, sex
    • professional data: workplace categories (university, psychiatric hospital, outpatient service, research centre); location of the workplace (capital, county seat, rural town, small town, village); years of professional experience; current psychotherapeutic activity
    • personal information (related to a stigmatizing attitude): mental illness is known in his/her family or close friend, previous treatment for own mental illness, attending psychotherapy
  • National version of the Opening Minds Stigma Scale for Health Care Providers (OMS-HC)

An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary, and it can be terminated at any time without having to give any reasons.

02

Conditions studied

  • Mental Illness
  • Stigmatization

Keywords

  • Stigma
  • Mental health related stigma
  • Stigmatising attitude
  • Mental health problems
  • Survey
  • Psychiatry
  • Psychiatrist
03

In context

Mental Disorders

1,740 studies on the registry are indexed under Mental Disorders; 348 are open to participants now.

This study's enrollment of 4,245 is above the median of 220 across 389 observational studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Semmelweis University is the lead sponsor of 140 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Practising specialists and trainees in adult psychiatry or child and adolescent psychiatry who work in the participating European countries

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The responder must be a practising specialist or trainee in psychiatry or child and adolescent psychiatry in one of the participating countries on the basis of his / her own declaration.
  • Responders could provide their consent by choosing "I agree" on the website, after reading the information leaflet and the form. Only those participants will be able to complete the online survey who chose "I agree" on the website.

Exclusion criteria

Exclusion Criteria:

  • The choice of "I do not agree" option of the participant on the website after reading the form. The responder will be guided automatically to the end of the survey.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
4,245 participants (actual)
Patient registry
No

Groups and cohorts

  • Trainees and specialists in child and adult psychiatry

    The responder must be a practising specialist or trainee in psychiatry or child and adolescent psychiatry in the participating European countries on the basis of his / her own declaration. Responders could provide their consent by choosing "I agree" on the website, after reading the information leaflet and the informed consent form.

    Other: anonymous online survey

Interventions

  • Otheranonymous online survey

    An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.

06

What researchers measure

Primary outcomes

  1. stigmatising attitude

    The main questionnaire is the Opening Minds Stigma Scale for Health Care Providers (OMS-HC) which is a self-report questionnaire that contains 15 statements describing feelings and opinions about people with mental health problems. . In the survey, the subjects indicate on a 5-point Likert scale (1 = "strongly disagree" to 5 = "strongly agree") the extent they identify themselves with the given statement. The overall stigmatising attitude of the participants is described with the total score of the scale (minimum of 15, and a maximum of 75 points). Besides the total score, three dimensions can be calculated by evaluating the three subscales of the questionnaire (Attitude, Disclosure and Help-seeking, and Social Distance). Higher scores on a subscale and higher total scores reflect a more stigmatising attitude.

    Time frame: Baseline

07

Study locations

31 sites
  • Xhavit Gjata Hospital
    Tirana, Albania
  • Department of Psychiatry and Psychotherapeutic Medicin, Medical University of Graz
    Graz, Austria
  • City Hospital N15
    Baku, Azerbaijan
  • Psychiatric Clinic of Minsk City
    Minsk, Belarus
  • Military Medical Academy, Department of Psychiatry
    Sofia, Bulgaria
  • University Hospital Centre Zagreb
    Zagreb, Croatia
  • Private Practice
    Nicosia, Cyprus
  • 3rd Faculty of Medicine, Charles University
    Prague, Czechia
  • Research Unit for Child and Adolescent Psychiatry, Psychiatry- Aalborg University Hospital
    Aalborg, Denmark
  • University of Tartu
    Tartu, Estonia
  • EPSM Étienne Gourmelen
    Quimper, France
  • Klinikum rechts der Isar der Technischen Universität München
    Munich, Germany
  • Department of Psychiatry, Faculty of Medicine, School of Health Sciences, University of Ioannina
    Ioánnina, Greece
  • Semmelweis University
    Budapest, 1085, Hungary
  • Department of Liasion Psychiatry, Mater University Hospital
    Dublin, Ireland
  • University Magna Graecia of Catanzaro
    Catanzaro, Italy
  • Hospital Gintermuiza
    Jelgava, Latvia
  • Vilnius University, Facutly of Medicine, Psychiatric Clinic
    Vilnius, Lithuania
  • Mount Carmel Hospital
    Attard, Malta
  • Clinical Centre of Montenegro, Clinic for Psychiatry
    Podgorica, Montenegro
  • Erasmus University
    Rotterdam, Netherlands
  • Institute of Psychological Medicine, Faculty of Medicine of University of Coimbra
    Coimbra, Portugal
  • The Serbsky State Scientific Center for Social and Forensic Psychiatry
    Moscow, Russian Federation
  • Institute for Mental Health
    Belgrade, Serbia
  • Psychiatric Hospital Michalovce
    Michalovce, Slovakia
  • Centre for Clinical Psychiatry, University Psychiatric Clinic and Children's hospital Ljubljana
    Ljubljana, Slovenia
  • Fidmag Foundation
    Barcelona, Spain
  • Psychiatrische Klinik Clienia Littenheid
    Littenheid, Switzerland
  • Ankara City Hospital Bilkent
    Ankara, Turkey
  • Chernivtsi Regional Mental Hospital, Bukovinian State Medical University
    Chernivtsi, Ukraine
  • Pennine Care NHS Foundation Trust
    Oldham, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jul 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2020
First posted
Nov 25, 2020
StartActual
Jul 29, 2020
Primary completionActual
Jul 31, 2021
CompletionActual
Jul 31, 2022
Last update
Oct 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04644978
Responsible party
Dorottya Ori (Principal investigator, MD, Semmelweis University) — Principal investigator
First posted
Nov 25, 2020
Start date
Jul 29, 2020
Primary completion
Jul 31, 2021
Completion
Jul 31, 2022
Last update
Oct 27, 2022

Study contacts

Dorottya Ori, MD
principal investigator · Vadaskert Child and Adolescent Psychiatric Hospital, Budapest, Hungary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion